WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317355
CAS#: 28395-03-1
Description: Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in people in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche. The main difference between the two substances is in bioavailability and pharmacodynamic potency. Furosemide is incompletely absorbed in the intestine (60%), and there are substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is almost completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.
MedKoo Cat#: 317355
Name: Bumetanide
CAS#: 28395-03-1
Chemical Formula: C17H20N2O5S
Exact Mass: 364.10929
Molecular Weight: 364.4161
Elemental Analysis: C, 56.03; H, 5.53; N, 7.69; O, 21.95; S, 8.80
Bumetanide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: Bumetanide, Trade names: Bumex or Burinex; PF 1593, PF-1593, PF1593
IUPAC/Chemical Name: 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
InChi Key: MAEIEVLCKWDQJH-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
SMILES Code: O=C(O)C1=CC(S(=O)(N)=O)=C(OC2=CC=CC=C2)C(NCCCC)=C1
The following data is based on the product molecular weight 364.4161 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Mitsui R, Hashitani H. Mechanisms underlying spontaneous constrictions of
postcapillary venules in the rat stomach. Pflugers Arch. 2015 Nov 4. [Epub ahead
of print] PubMed PMID: 26530829.
2: Krueger D, Michel K, Zeller F, Demir IE, Ceyhan GO, Slotta-Huspenina J,
Schemann M. Neural influences on human intestinal epithelium in vitro. J Physiol.
2015 Nov 2. doi: 10.1113/JP271493. [Epub ahead of print] PubMed PMID: 26527433.
3: Pressler RM, Boylan GB, Marlow N, de Vries LS, Blennow M, Chiron C, Cross JH,
Hallberg B, Hellström-Westas L, Jullien V, Mangum B, Murphy B, Murray D, Pons G,
Rennie J, Toet MC, Zohar S; NEMO consortium (NEonatal seizure treatment with
Medication Off-patent). Bumetanide for neonatal seizures-back from the cotside.
Nat Rev Neurol. 2015 Nov 3. doi: 10.1038/nrneurol.2015.116. [Epub ahead of print]
PubMed PMID: 26526530.